Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

ToeFX Light Therapy for Chronic Venous Leg Ulcers

13 novembre 2026 aggiornato da: Dr. Ahmed Kayssi

Adjunctive ToeFX Photodynamic Therapy for Chronic Venous Leg Ulcers: A Single-Arm, Open-Label Pilot Feasibility Study

Chronic venous leg ulcers can be painful and prone to infection. They can significantly limit a patient's function, mobility and quality of life.

A major contributor to delayed ulcer healing is persistent bacteria. Treatments that can penetrate the bacteria's protective outer shield to kill and clear the bacteria are important for helping ulcers heal more quickly.

The purpose of this pilot study is to test a topical study treatment (called ClearToe Serum®) plus two types of light (red and blue-purple light) in the treatment of chronic venous ulcers.

This is an open-label single-arm pilot study. All participants will receive the test treatment as well as standard or care treatment for their chronic venous ulcer. Participants will receive study treatments one per week for up to 12 weeks, or until their ulcer is healed.

The main objectives are to assess adherence to the one-per-week study treatments, and to note any study device-related, study treatment-related, or serious adverse events, or adverse events that lead to stopping study treatment.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

Chronic venous leg ulcers (VLUs) are a common and costly. They affect about 1% adults and are a significant burden to patients and the healthcare system. VLUs are often painful, malodorous, and prone to infection. They can have a big impact a patient's function, mobility, and quality of life. Standard of care (SOC) treatment, meaning the usual treatment, includes compression therapy, regular wound care (removing dead tissue, cleaning and dressing the wound), and infection management. Even with SOC treatment, about half of VLUs persist for months or years.

A major contributor to delayed healing is persistent bacterial infection, including bacteria that produce a biofilm, a protective covering resistant to many topical and systemic antibiotics. Strategies that can penetrate the biofilm to reduce local bacterial infection without contributing to antibiotic resistance are of particular interest in chronic wound management.

ToeFX has developed a non-thermal photodynamic therapy (PDT) platform that combines a methylene-blue-based photosensitizer (ClearToe® serum) with 660 nm light irradiation. Upon activation by light of the appropriate wavelength, the photosensitizer generates reactive oxygen species that are toxic to a broad range of bacteria but harmless for host tissue. This mechanism of photodynamic disinfection is well established in other clinical contexts, and the ToeFX platform is currently approved/registered for other indications. The ToeFX ClearToe® system is approved by Health Canada for the treatment of onychomycosis (toenail fungus). Its potential to reduce local bioburden and support a more favourable wound-healing environment has not yet been formally evaluated in venous leg ulcers.

This pilot study is intended to evaluate the feasibility (treatment adherence) and safety of ToeFX photodynamic therapy as an adjunct to SOC in a defined population of patients with chronic venous leg ulcers, while collecting preliminary clinical, wound-healing, and patient-reported outcome data to inform the design of a future, larger controlled trial.

Tipo di studio

Interventistico

Iscrizione (Stimato)

20

Fase

  • Non applicabile

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Ontario
      • Toronto, Ontario, Canada, M4L 3Y3
        • East Toronto Vascular Clinic
        • Contatto:

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Age 18 years or older
  • Able to attend weekly visits for up to 12 weeks
  • Chronic venous leg ulcer (CEAP C6) of the lower extremity
  • Ulcer duration of 4 weeks or more
  • Ulcer size between 1 cm² and 20 cm² at baseline
  • Receiving standard-of-care compression therapy, or eligible to initiate it
  • Able to provide informed consent and comply with study procedures

Exclusion Criteria:

  • Wound location or anatomy not compatible with the ToeFX photodynamic therapy device
  • Systemic infection (e.g., fever, sepsis, spreading cellulitis) or wound requiring systemic antibiotics
  • Necrotic tissue over 25% of the wound bed, exposed bone or tendon, deep abscess, osteomyelitis or gangrene
  • Severe ischemia (ABI below 0.5) or poorly controlled diabetes (HbA1c above 10%)
  • Heavy exudate requiring negative-pressure wound therapy
  • Known photosensitivity or allergy to methylene blue or light-based therapies
  • Immunosuppressive therapy, radiation or chemotherapy within the past 3 months, or active malignancy
  • Pregnancy or lactation
  • Known Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency
  • Participation in another interventional study within 30 days of screening

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Fattibilità del dispositivo
  • Assegnazione: N / A
  • Modello interventistico: Assegnazione di gruppo singolo
  • Mascheramento: Nessuno (etichetta aperta)

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: ToeFX Treatment

Weekly ToeFX treatment of venous leg ulcer up to 12 weeks or wound closure

Non-thermal photodynamic therapy platform that combines a methylene-blue-based photosensitizer ( ClearToe® serum) with 660 nm light irradiation

Altri nomi:
  • ToeFX
  • ClearToe Serum

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Treatment adherence
Lasso di tempo: Baseline through Visit 12/ end of treatment (up to 12 weeks)

Percentage of planned ToeFX treatment sessions completed per participant, and reasons for missed or discontinued sessions

Baseline through Visit 12/ end of treatment (up to 12 weeks)
Safety: Adverse Events
Lasso di tempo: Baseline through Healing Confirmation Visit (up to 14 weeks)

Incidence and severity of adverse events (AEs), serious adverse events (SAEs), device-related AEs, treatment-related AEs, and study discontinuations due to AEs

Baseline through Healing Confirmation Visit (up to 14 weeks)

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Percent Change in Wound Area From Baseline
Lasso di tempo: Baseline, week 4, week 8, and week 12

Percent change in wound area (cm²) from baseline

Baseline, week 4, week 8, and week 12
Complete wound epithelialization
Lasso di tempo: 12 weeks

Proportion of participants achieving complete epithelialization by Week 12, as assessed by clinician

12 weeks
Time to complete wound healing
Lasso di tempo: 12 weeks

Time (days) from baseline to complete epithelialization

12 weeks
Change in Bates-Jensen Wound Assessment Tool (BWAT) score
Lasso di tempo: Baseline to 12 weeks/ end of treatment

Change in wound bed characteristics measured using the BWAT

Baseline to 12 weeks/ end of treatment
Change in pain score
Lasso di tempo: Baseline to 12 weeks/ end of treatment

Change in pain score (0-10 Numeric Rating Scale)

Baseline to 12 weeks/ end of treatment
Change in health-related quality of life
Lasso di tempo: 12 weeks/ end of treatment

Change in EQ-5D-5L score

12 weeks/ end of treatment
Patient satisfaction
Lasso di tempo: 12 weeks/ end of treatment

Patient-reported satisfaction with treatment measured by study-specific patient satisfaction questionnaire

12 weeks/ end of treatment
Clinician feasibility
Lasso di tempo: 14 weeks or earlier if wound healing

Qualitative and operational observations on feasibility of integrating PDF into routine wound care workflow

14 weeks or earlier if wound healing
Absolute Change in Wound Area From Baseline
Lasso di tempo: Baseline, week 4, week 8, and week 12

Absolute change in wound area (cm²) from baseline

Baseline, week 4, week 8, and week 12

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Investigatore principale: Ahmed Kayssi, MD MSc FRCSC, East Toronto Vascular Clinic

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

15 novembre 2026

Completamento primario (Stimato)

31 ottobre 2027

Completamento dello studio (Stimato)

31 ottobre 2027

Date di iscrizione allo studio

Primo inviato

13 novembre 2026

Primo inviato che soddisfa i criteri di controllo qualità

13 novembre 2026

Primo Inserito (Effettivo)

19 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

19 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

13 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Parole chiave

Altri numeri di identificazione dello studio

  • PRO04244160_ToeFX

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

NO

Descrizione del piano IPD

This is a small single-centre pilot study. Individual participant data will not be shared because of participant privacy considerations and the terms of the clinical trial agreement with the study funder. Data are de-identified using study IDs and stored with restricted access. Aggregate results will be published.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .